In hepatocytes and tumor cells alike, metformin reduces hepatic gluconeogenesis and systemic insulin levels, thereby blunting the insulin/IGF-1 signaling cascade implicated in tumorigenesis [10]. The gene discussed is INS; the disease is neoplasm.